EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 15th, 2021 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the 30th day of September, 2020, between Jeff Rona (“Executive”) and OVID THERAPEUTICS INC. (the “Company”). Certain capitalized terms used in this Agreement are defined in Section 6.
COLLABORATION AND LICENSE AgreementCollaboration and License Agreement • March 15th, 2021 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
This Collaboration and License Agreement (the “Agreement”) is entered into as of July 8, 2020 (the “Effective Date”), by and between Ovid Therapeutics Inc., a Delaware company having an address at 1460 Broadway, Suite 15021 New York, NY 10036, USA (“Ovid”) and Angelini Pharma Rare Diseases AG, a Swiss company under direction and control of Angelini Pharma S.p.A. and having an address at Consulting GmbH Sumpfstrasse 26 6312 Steinhausen, Zurich, Switzerland (“Licensee”). Ovid and Licensee may be referred to herein individually as a “Party” or collectively as the “Parties”.
